出版物 Vebreltinib (APL-101) 原代号为 CBT-101 Apollomics: Preliminary Results of Phase II KUNPENG Study of Vebreltinib in Patients (Pts) with Advanced NSCLC Harboring c-MET Alterations ENA 2020: Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor Cell:2018.11 Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. SITC 2018: Combination immunotherapy anti-PD-1 antibody with CBT-101 (c-MET inhibitor) demonstrates enhanced activity in tumors not dependent on c-MET AACR 2017: Bozitinib, a highly selective inhibitor of c-MET, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models APL-102 (mKi) 原代号为 CBT-102 AACR 2019: APL-102, an oral small molecule multi-kinase inhibitor, demonstrates favorable CSF-1R activity, offering a means for controlling tumor associated macrophages AACR 2018: CBT-102, an oral multi-kinase small molecule, demonstrates favorable activity in LIMsh050 and PLCPRF5 human hepatocellular carcinoma animal models and cardiac safety in rabbit Purkinje and Beagle dogs compared to sorafenib APL-501 原代号为 CBT-501 SITC 2017: A phase 1 multicenter, dose escalation study of CBT-501, a novel anti-PD-1 inhibitor in subjects with select advanced or relapsed/recurrent solid tumors ASCO-SITC 2017: CBT-501, a novel humanized anti-PD-1 antibody shows differentiated activity in a humanized genetically engineered mouse model of colon carcinoma
